OPALINE Study: Observational Study in a Real-World Setting of the Systemic Treatment of Progressive Unresectable or Well-Differentiated Metastatic Pancreatic Neuroendocrine Tumors (pNET)

#2004

Introduction: OPALINE Study focuses on patients with pNET. 2 targeted therapies (TT) offer new options to treat these patients: mTORi (everolimus) and a multi-targeted inhibitor (sunitinib).

Aim(s): Evaluate the impact of both TT versus other treatments (OT) for pNET in a real-world clinical setting.

Materials and methods: We expected 150 patients with well differentiated, progressive, unresectable or metastatic pNET, naïve or pretreated (<5 lines). 2 groups are opened: TT group and OT group (chemotherapy (C), SSA, IFN-α and PRRT).

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Lombard-Bohas C, Lepage C, Vicaut E, Dominguez S, Coriat R,

Keywords: pNET, targeted therapies,

To read the full abstract, please log into your ENETS Member account.

OPALINE Study: Observational Study in a Real-World Setting of the Systemic Treatment of Progressive Unresectable or Well-Differentiated Metastatic Pancreatic Neuroendocrine Tumors (pNET).

#1842

Introduction: OPALINE Study focuses on patients with pNET. Two targeted therapies (TT) offer new options to treat these patients: mTORi (everolimus) and a multi-targeted inhibitor (sunitinib).

Aim(s): Evaluate the impact of both TT vs other treatments (OT) for pNET in a real-world clinical setting.

Materials and methods: We expected 150 patients with well differentiated, progressive, unresectable or metastatic pNET, naïve or pretreated (<5 lines). 2 cohorts are opened TT group; OT group (chemotherapy,SSA, interferon-alpha and vectorized internal radiation therapy).

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Lombard-Bohas V

Authors: Lombard-Bohas C, Lepage C, Vicaut E, Dominguez S, Coriat R,

Keywords: pNET, targeted therapy,

To read the full abstract, please log into your ENETS Member account.